We were very excited for this gigantic effort with our colleagues on the CCC-19, COVID-19 and cancer consortium. And just to remind the audience, this is a voluntary effort using crowdsourcing. So we’d reached out to multiple cancer centers. We now have 124 institutions signed up in this consortium and this registry. And we try to have data collection from patients who have cancer and COVID-19, and those surveys are being filled out by the providers who take care of those patients, trying to capture gala and detailed data about demographic factors, clinical factors, pathologic factors, and laboratory factors that could potentially have prognostic value in order to increase our understanding of the COVID-19 pandemic and how we can use this data to inform our day to day discussions in the context of diagnosis and treatment of cancer...
We were very excited for this gigantic effort with our colleagues on the CCC-19, COVID-19 and cancer consortium. And just to remind the audience, this is a voluntary effort using crowdsourcing. So we’d reached out to multiple cancer centers. We now have 124 institutions signed up in this consortium and this registry. And we try to have data collection from patients who have cancer and COVID-19, and those surveys are being filled out by the providers who take care of those patients, trying to capture gala and detailed data about demographic factors, clinical factors, pathologic factors, and laboratory factors that could potentially have prognostic value in order to increase our understanding of the COVID-19 pandemic and how we can use this data to inform our day to day discussions in the context of diagnosis and treatment of cancer. So how do we deal, how do we diagnose and treat patients with cancer who when infected with SARS-COV2 virus?
So they have cancer and COVID-19. So that’s the mission of our consortium is to generate this very important gala data regarding the different clinical pathologic factors, treatment and related data in patients with cancer and COVID-19. In the presentations I had to give, and had the opportunity to give at the ESMO virtual meeting, we’re able to explore different laboratory factors as potential prognostic variables in patients with cancer and COVID-19, in the subset of patients who were hospitalized. And also would try to validate our priority identified clinical pathologic factors that we previously published in the Lancet paper May 28, 2020. And then this new publication, with this presentation at ESMO, and hopefully future publication, we’re able to validate the prognostic value of some of those clinical pathologic variables. And I think it’s very important that we’ll have the chance to present the data at ESMO 2020.
